XML 51 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Information (Tables)
 12 Months Ended
Dec. 31, 2024
Segment Information [Abstract]  
Segment Information

The following table sets forth information on segment profit or loss, including significant segment expenses (in thousands):

 
Year Ended December 31,
  
   
2024
    
2023
    
2022
  
                   
Revenue
  
$
705,138
    
$
787,647
    
$
587,367
  
                         
Less:
                        
Cost of sales
    
10,415
      
8,686
      
13,447
  
Drug discovery
    
114,350
      
125,649
      
181,302
  
Drug development
    
527,259
      
530,332
      
426,225
  
Medical affairs
    
27,229
      
19,454
      
15,948
  
Manufacturing and development chemistry
    
57,729
      
65,293
      
76,162
  
R&D support
    
82,559
      
81,019
      
59,840
  
Selling, general and administrative
    
230,478
      
205,135
      
124,370
  
Other segment items (1)
    
109,016
      
118,365
      
(40,205
)
                         
Consolidated net loss
  
$
(453,897
)
  
$
(366,286
)
  
$
(269,722
)

(1)
Other segment items include stock-based compensation expense, investment income, interest expense, gain or loss on investments, other income or expense and income tax expense or benefit.